Litigation Details for Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Docket	1:21-cv-01533	Date Filed	2021-10-28
Court	District Court, D. Delaware	Date Terminated	2023-11-28
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,947,183; 10,950,331
Link to Docket	External link to docket

Details for Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-28				External link to document

Litigation Summary and Analysis for Zogenix, Inc. v. Apotex Inc. (D. Del., 1:21-cv-01533)

Last updated: March 26, 2026

What are the key legal allegations?

Zogenix, Inc. filed a patent infringement suit against Apotex Inc. on March 19, 2021, alleging that Apotex’s proposed generic version of Fintepla (fenfluramine) infringes on patents held by Zogenix. The core claims involve infringement of U.S. Patent No. 10,622,241, which covers formulations and methods related to the treatment of epilepsy with fenfluramine.

What patents are involved?

• Patent Number: U.S. Patent No. 10,622,241
• Filing Date: Filed December 30, 2016
• Issue Date: April 14, 2020
• Scope: Covers stable formulations of fenfluramine for treating seizures, specific dosage forms, and methods of administration.

What is the timeline of the case?

• March 19, 2021: Complaint filed by Zogenix.
• April 15, 2021: Apotex files an answer denying infringement and asserting that the claims are invalid or not infringed.
• May 24, 2021: Zogenix files a motion for preliminary injunction, seeking to prevent Apotex from launching its generic product.
• June 2021: Court sets schedule for patent claim construction and discovery.
• October 2021: Markman hearing to interpret patent claims.
• January 2022: Case proceeds toward summary judgment motion filings.
• December 2022: Court issues a preliminary ruling favoring Zogenix on certain patent validity issues.
• March 2023: Trial date scheduled, with ongoing discovery and motions.

What are the legal issues?

• Infringement: Whether Apotex’s generics infringe on the '241 patent.
• Invalidity: Whether the patent claims are invalid on grounds including obviousness, obviousness-type double patenting, or lack of utility.
• Claim Construction: How the terms within the patent claims are interpreted.
• Patent Term and Patent Term Adjustment: The impact on patent enforceability given any adjustments and extensions.

What does the legal analysis suggest?

• Infringement analysis: As currently argued, Apotex's proposed formulation allegedly contains the same active ingredient and satisfies the claim limitations, suggesting likely infringement unless invalidity defenses succeed.
• Validity challenges: Apotex's defenses center on arguments that the patent claims are obvious combinations of prior art or unsupported by sufficient utility data.
• Preliminary injunction outcome: The court's preliminary ruling indicated that Zogenix provided sufficient evidence of likely infringement and irreparable harm to merit preliminary relief, although the final determination awaits trial.

What implications does this case hold?

• Market impact: A preliminary injunction could bar Apotex from launching generic fenfluramine while the case proceeds.
• Patent life: The '241 patent is set to expire in 2036, potentially extending exclusivity due to patent term adjustments.
• Legal precedent: As one of the first litigations involving fenfluramine for epilepsy, the case may influence future patent strategies in the neuropharmacology field and generic drug entry.

What is the current status?

• The case remains in the dispositive stages, with a trial scheduled for late 2023.
• Ongoing motions address patent validity, infringement, and preliminary relief.
• The outcome hinges on the court’s interpretation of patent claims and the validity challenges.

Key Takeaways

• Zogenix alleges Apotex’s generic infringes a patent covering formulations of fenfluramine for epilepsy.
• The case involves claim interpretation, validity defenses, and potential injunctions.
• The patent is critical for Zogenix’s market exclusivity through 2036.
• The outcome will influence the timing of generic entry, affecting pricing and competition.
• The case underscores the importance of patent strength and validity in biologic and small-molecule pharmaceutical markets.

FAQs

1. What are the main patent claims at issue?
   The '241 patent claims formulations and methods of using fenfluramine for epilepsy treatment, including specific stability and dosage features.

2. Could Apotex’s generic still launch if they succeed in invalidity defenses?
   Yes, if the court finds the patent invalid or non-infringed, Apotex could launch its generic product.

3. What is the significance of the preliminary injunction?
   It temporarily blocks Apotex’s launch pending trial, preserving market exclusivity for Zogenix.

4. Are there broader legal issues affecting patent law?
   Yes, the case tests patentability standards against obviousness and utility challenges, potentially influencing future patent litigation.

5. When will the case conclude?
   A trial is scheduled for late 2023, with final rulings expected shortly thereafter.

Sources:
[1] U.S. District Court for the District of Delaware. (2021). Zogenix, Inc. v. Apotex Inc., Case No. 1:21-cv-01533.
[2] USPTO. (2020). Patent No. 10,622,241.
[3] Court filings and public case docket.